By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Simulations Plus, Inc.

Simulations Plus, Inc. (SLP)

NASDAQ Currency in USD
$139.00
+$2.18
+1.59%
Last Update: 18 Jul 2026, 13:45
$2.79bn
Market Cap
347.85
P/E Ratio (TTM)
Forward Dividend Yield
$92.83-$183.90
52 Week Range

SLP Stock Price Chart

Explore Simulations Plus, Inc. interactive price chart. Choose custom timeframes to analyze SLP price movements and trends.

SLP Company Profile

Discover essential business fundamentals and corporate details for Simulations Plus, Inc. (SLP) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Healthcare Information Services

IPO Date

18 Jun 1997

Employees

243.00

CEO

Shawn O'Connor

Description

Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.

SLP Financial Timeline

Browse a chronological timeline of Simulations Plus, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 7 Dec 2026

EPS estimate is $0.14, while revenue estimate is $19.14m.

Upcoming earnings on 28 Oct 2026

EPS estimate is $0.13, while revenue estimate is $17.59m.

Earnings released on 9 Jul 2026

EPS came in at $0.30 surpassing the estimated $0.23 by +29.03%, while revenue for the quarter reached $21.89m , beating expectations by +4.74%.

Earnings released on 9 Apr 2026

EPS came in at $0.35 surpassing the estimated $0.27 by +29.63%, while revenue for the quarter reached $24.29m , beating expectations by +12.15%.

Earnings released on 8 Jan 2026

EPS came in at $0.13 falling short of the estimated $0.18 by -27.78%, while revenue for the quarter reached $18.42m , beating expectations by +1.99%.

Earnings released on 1 Dec 2025

EPS came in at $0.10 matching the estimated $0.10, while revenue for the quarter reached $17.46m , beating expectations by +0.41%.

Earnings released on 14 Jul 2025

EPS came in at $0.45 surpassing the estimated $0.26 by +73.08%, while revenue for the quarter reached $20.36m , missing expectations by -2.69%.

Earnings released on 3 Apr 2025

EPS came in at $0.31 surpassing the estimated $0.25 by +24.00%, while revenue for the quarter reached $22.43m , beating expectations by +2.31%.

Earnings released on 7 Jan 2025

EPS came in at $0.17 falling short of the estimated $0.18 by -5.56%, while revenue for the quarter reached $18.92m , beating expectations by +0.63%.

Earnings released on 23 Oct 2024

EPS came in at $0.06 falling short of the estimated $0.07 by -9.09%, while revenue for the quarter reached $18.66m , missing expectations by -5.45%.

Dividend declared on 29 Jul 2024

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 5 Aug 2024.

Earnings released on 2 Jul 2024

EPS came in at $0.15 matching the estimated $0.15, while revenue for the quarter reached $18.54m , missing expectations by -6.39%.

Dividend declared on 26 Apr 2024

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 6 May 2024.

Earnings released on 3 Apr 2024

EPS came in at $0.20 surpassing the estimated $0.19 by +5.26%, while revenue for the quarter reached $18.31m , beating expectations by +5.93%.

Dividend declared on 26 Jan 2024

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 5 Feb 2024.

Earnings released on 3 Jan 2024

EPS came in at $0.10 matching the estimated $0.10, while revenue for the quarter reached $14.50m , beating expectations by +4.17%.

Dividend declared on 27 Oct 2023

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 6 Nov 2023.

Earnings released on 25 Oct 2023

EPS came in at $0.18 matching the estimated $0.18, while revenue for the quarter reached $15.63m , missing expectations by -7.03%.

Dividend declared on 28 Jul 2023

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 7 Aug 2023.

Earnings released on 6 Jul 2023

EPS came in at $0.20 matching the estimated $0.20, while revenue for the quarter reached $16.23m , missing expectations by -3.43%.

Dividend declared on 21 Apr 2023

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 1 May 2023.

Earnings released on 5 Apr 2023

EPS came in at $0.20 surpassing the estimated $0.18 by +11.11%, while revenue for the quarter reached $15.75m , missing expectations by -2.36%.

Dividend declared on 27 Jan 2023

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 6 Feb 2023.

Earnings released on 4 Jan 2023

EPS came in at $0.06 falling short of the estimated $0.09 by -33.33%, while revenue for the quarter reached $11.96m , missing expectations by -3.20%.

Dividend declared on 28 Oct 2022

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 7 Nov 2022.

Earnings released on 26 Oct 2022

EPS came in at $0.07 falling short of the estimated $0.09 by -22.22%, while revenue for the quarter reached $11.73m , beating expectations by +7.40%.

Dividend declared on 22 Jul 2022

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 1 Aug 2022.

Earnings released on 6 Jul 2022

EPS came in at $0.20 surpassing the estimated $0.18 by +11.11%, while revenue for the quarter reached $14.96m , beating expectations by +4.30%.

Dividend declared on 22 Apr 2022

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 2 May 2022.

Earnings released on 6 Apr 2022

EPS came in at $0.21 surpassing the estimated $0.14 by +50.00%, while revenue for the quarter reached $14.80m , beating expectations by +2.09%.

Dividend declared on 28 Jan 2022

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 7 Feb 2022.

Earnings released on 6 Jan 2022

EPS came in at $0.15 surpassing the estimated $0.09 by +66.67%, while revenue for the quarter reached $12.42m , beating expectations by +21.21%.

Earnings released on 25 Oct 2021

EPS came in at $0.01 falling short of the estimated $0.08 by -87.50%, while revenue for the quarter reached $9.84m , beating expectations by +20.45%.

Dividend declared on 22 Oct 2021

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 1 Nov 2021.

Dividend declared on 23 Jul 2021

A dividend of $0.06 per share was announced, adjusted to $0.06. The dividend was paid on 2 Aug 2021.

SLP Stock Performance

Access detailed SLP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run